TABLE 3.
TEAEs in ≥20% of patients by cohort
| Cohort A1: cHL (anti‐PD‐1/PD‐L1 naïve) (n = 18) | Cohort A2: cHL (anti‐PD‐1/PD‐L1 progressors) (n = 12) | Cohort B: DLBCL (n = 17) | Cohort C: PTCL (n = 11) | |||||
|---|---|---|---|---|---|---|---|---|
| All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | |
| Any event | 15 (83.3) | 1 (5.6) | 12 (100) | 1 (8.3) | 17 (100) | 12 (70.6) | 11 (100) | 9 (81.8) |
| Infusion‐related reaction | 7 (38.9) | 0 | 9 (75.0) | 0 | 9 (52.9) | 0 | 8 (72.7) | 1 (9.1) |
| Pyrexia | 4 (22.2) | 0 | 3 (25.0) | 0 | 2 (11.8) | 0 | 2 (18.2) | 1 (9.1) |
| Diarrhea | 3 (16.7) | 0 | 3 (25.0) | 0 | 4 (23.5) | 0 | 1 (9.1) | 0 |
| Peripheral edema | 3 (16.7) | 0 | 0 | 0 | 5 (29.4) | 1 (5.9) | 1 (9.1) | 0 |
| Pruritus | 2 (11.1) | 0 | 3 (25.0) | 0 | 0 | 0 | 1 (9.1) | 0 |
| Abdominal pain | 2 (11.1) | 0 | 1 (8.3) | 0 | 5 (29.4) | 1 (5.9) | 0 | 0 |
| Decreased appetite | 2 (11.1) | 0 | 0 | 0 | 4 (23.5) | 2 (11.8) | 0 | 0 |
| Nausea | 1 (5.6) | 0 | 4 (33.3) | 0 | 4 (23.5) | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 1 (8.3) | 0 | 4 (23.5) | 0 | 1 (9.1) | 0 |
| Hematological laboratory abnormalities | ||||||||
| Anemia | 16 (88.9) | 1 (5.6) | 7 (58.3) | 0 | 16 (100) | 2 (12.5) | 11 (100) | 2 (18.2) |
| Lymphopenia | 12 (66.7) | 5 (27.8) | 3 (25.0) | 1 (8.3) | 14 (87.5) | 7 (43.8) | 10 (90.9) | 4 (36.4) |
| Neutropenia | 3 (16.7) | 0 | – | – | 6 (37.5) | 3 (18.8) | 6 (54.5) | 2 (18.2) |
| Leukopenia | 10 (55.6) | 0 | 2 (16.7) | 0 | 13 (81.3) | 3 (18.8) | 8 (72.7) | 2 (18.2) |
| Thrombocytopenia | 7 (38.9) | 0 | 3 (25.0) | 0 | 11 (68.8) | 2 (12.5) | 8 (72.7) | 4 (36.4) |
Note: All data are shown as n (%).
Abbreviations: cHL, classic Hodgkin's lymphoma; DLBCL, diffuse large B‐cell lymphoma; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PTCL, peripheral T‐cell lymphoma; TEAE, treatment‐emergent adverse event.